Induction of endothelium-dependent constriction of mesenteric arteries in endotoxemic hypotensive shock

Br J Pharmacol. 2016 Apr;173(7):1179-95. doi: 10.1111/bph.13415. Epub 2016 Mar 6.

Abstract

Background and purpose: Effective management of hypotension refractory to vasoconstrictors in severe sepsis is limited. A new strategy to ameliorate endotoxemic hypotension by inducing endothelium-dependent constriction of large arteries was assessed.

Experimental approach: Endotoxemia in rats was induced by injection of LPS (10 mg·kg(-1), i.v.). Haemodynamics were measured in vivo, reactivity of isolated mesenteric arteries by myography and expression of proteins and enzyme activities by immunohistochemistry, biochemistry and molecular biology.

Key results: Six hours after LPS, the hypotension was promptly reversed following injection (i.v. or i.p.) of oroxylin-A (OroA) . In isolated LPS-treated but not normal mesenteric arteries, OroA (1-10 μM) induced endothelium-dependent, sustained constriction, blocked by endothelin-1 (ET-1) receptor antagonists. OroA further enhanced LPS-induced expression of endothelin-converting enzyme, ET-1 mRNA and proteins and ET-1 release, OroA also enhanced phosphorylation of Rho-associated protein kinase (ROCK) and reversed LPS-induced suppression of RhoA activities in smooth muscle of arteries with endothelium. Activated- phosphorylation of smooth muscle ROCK was blocked by ET-1-receptor antagonists and ROCK inhibitors. Moreover, OroA post-treatment suppressed, via inhibiting NF-κB activation, inducible NOS expression and circulating NO.

Conclusions and implications: Reversal of endotoxemic hypotensive by OroA was due to release of endothelial ET-1, upregulated by LPS, from mesenteric arteries, inducing prompt and sustained vasoconstriction via activation of vascular smooth muscle RhoA/ROCK-pathway. In late endotoxemia, OroA-induced vasoconstriction was partly due to decreased circulating NO. Activation of endothelium-dependent constriction in large resistance arteries and suppression of systemic inflammation offer new strategies for acute management of endotoxemic hypotensive shock.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Endothelin A Receptor Antagonists / therapeutic use*
  • Endothelin-1 / metabolism
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology
  • Endotoxemia / drug therapy*
  • Endotoxemia / physiopathology
  • Flavonoids / therapeutic use*
  • Hypotension / drug therapy*
  • Hypotension / physiopathology
  • Lipopolysaccharides / pharmacology
  • Male
  • Mesenteric Arteries / drug effects*
  • Mesenteric Arteries / physiopathology
  • Nitric Oxide / biosynthesis
  • Nitric Oxide Synthase Type II / metabolism
  • Phosphorylation
  • Rats, Sprague-Dawley
  • Shock, Septic / drug therapy*
  • Shock, Septic / physiopathology
  • Vasoconstriction
  • rho-Associated Kinases / antagonists & inhibitors
  • rho-Associated Kinases / metabolism
  • rhoA GTP-Binding Protein / metabolism

Substances

  • Endothelin A Receptor Antagonists
  • Endothelin-1
  • Flavonoids
  • Lipopolysaccharides
  • Nitric Oxide
  • 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one
  • Nitric Oxide Synthase Type II
  • rho-Associated Kinases
  • rhoA GTP-Binding Protein